Ftse Mib
33.739,90
-0,08%
DAX
19.848,77
-0,34%
S&P 500
6.040,04
1,10%
NASDAQ
0,00
0,00%
Bitcoin
95.450,00
-3,88%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ KalVista Pharmaceuticals Inc (KALV) KalVista Pharmaceuticals Inc (KALV) Notizie

KALV

KalVista Pharmaceuticals (KALV)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KALV
DataOraFonteTitoloSimboloCompagnia
16/12/202413:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KALVKalVista Pharmaceuticals Inc
16/12/202413:00Business WireKalVista Appoints Jeb Ledell as Chief Operating OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
10/12/202403:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202422:07Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KALVKalVista Pharmaceuticals Inc
05/12/202412:30Business WireKalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
04/12/202412:30Business WireKalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202422:39Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KALVKalVista Pharmaceuticals Inc
26/11/202413:00Business WireKalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of DirectorsNASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202421:57Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
14/11/202418:02Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:KALVKalVista Pharmaceuticals Inc
12/11/202412:30Business WireKalVista Pharmaceuticals to Present at Upcoming Investor ConferencesNASDAQ:KALVKalVista Pharmaceuticals Inc
07/11/202420:34Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413:05Business WireKalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 MillionNASDAQ:KALVKalVista Pharmaceuticals Inc
04/11/202413:00Business WireKalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare TrustNASDAQ:KALVKalVista Pharmaceuticals Inc
28/10/202411:30Business WireKalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and ImmunologyNASDAQ:KALVKalVista Pharmaceuticals Inc
18/10/202412:30Business WireKalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)NASDAQ:KALVKalVista Pharmaceuticals Inc
04/10/202418:29Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at the 2024 HAEi Global Angioedema ForumNASDAQ:KALVKalVista Pharmaceuticals Inc
30/09/202412:30Business WireKalVista Announces the Submission of Additional Marketing Authorization Applications for Sebetralstat for the Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
26/09/202412:30Business WireKalVista Pharmaceuticals Announces Nine Abstracts Accepted for Presentation at the HAEi Global Angioedema Forum (GAF)NASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202413:00Business WireKalVista Pharmaceuticals to Participate in the 2024 Cantor Global Healthcare ConferenceNASDAQ:KALVKalVista Pharmaceuticals Inc
10/09/202412:30Business WireKalVista Appoints Brian Piekos as Chief Financial OfficerNASDAQ:KALVKalVista Pharmaceuticals Inc
06/09/202412:30Business WireKalVista Pharmaceuticals Presents Sebetralstat Data at Bradykinin Symposium 2024NASDAQ:KALVKalVista Pharmaceuticals Inc
05/09/202412:30Business WireKalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational UpdateNASDAQ:KALVKalVista Pharmaceuticals Inc
03/09/202412:30Business WireKalVista Announces FDA Acceptance of New Drug Application for Sebetralstat for Oral On-Demand Treatment of Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
29/08/202412:30Business WireKalVista Pharmaceuticals Announces Six Abstracts Accepted for Presentation at the 2024 Bradykinin SymposiumNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202422:17Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202422:13Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KALVKalVista Pharmaceuticals Inc
22/08/202422:08Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:KALVKalVista Pharmaceuticals Inc
15/08/202412:30Business WireKalVista Announces Validation of Marketing Authorization Application by the European Medicines Agency for Sebetralstat for Hereditary AngioedemaNASDAQ:KALVKalVista Pharmaceuticals Inc
22/07/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KALVKalVista Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KALV

La tua Cronologia

USOTC
NHCMF
NHC Comm (GM)
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network